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Through last two decades, transporters have been recognized as one of the important elements which 
plays an important role to regulate the ADME (Absorption, Distribution, Metabolism and Excretion) 
properties of drugs and xenobiotics. To evaluate the role of the transporters in drug development, an 
International Transporter Consortium (ITC) discussed about the identification of the clinically relevant 
transporters, application of these transporters in different drug-drug interaction (DDI) studies and the 
different criteria to determine whether additional DDI studies are required. Owing to the increase of 
transporter research studies in the last decade and the emphasis of the transporter mediated DDI by 
different regulatory agencies (FDA, EMA and PMDA), the incorporation of transporter related information 
in the different drug “Label” has increased from 24 % to 56 % within five years. In addition, the transporter 
related post marketing studies became quite important to address different questions regarding dose 
optimization and in the revision of drug product labelling. 
In general, the role of transporters varies depending on their function and localization within the gut 
lumen, liver, kidney and brain. Depending on the directions of the transport, they can be classified as either 
efflux or influx/uptake. Usually efflux transporters shuttle compounds out of the cell against the 
concentration gradient whereas the uptake transporters direct compounds into the cells along the 
concentration gradient. Since many transporters have the ability to recognize more than one substrate, 
different types of DDI have been noticed due to the inhibition and induction of the function of the 
transporters. In addition, many transporters demonstrated genetic polymorphisms which may affect their 
function.  
Traditionally, in vitro tools and preclinical animal experiments have often been used to assess the role 
of efflux transporters in drug development. Carefully designed and properly planned studies can give a 
clear understanding of the intrinsic functions and attributes of the study. The accumulation of the current 
in vitro and preclinical animal knowledge base is a conscious effort to link the clinical endpoints with the 
early developmental work which ultimately will help to identify the effect of drug transporters in the 
clinical settings. However, owing to the broad substrate specificity as well as significant overlap of inhibitor 
specificity, one should always investigate the experimental design and the results to determine the 
combined effects of particular transporters. Similarly, naturally occurring genetic variabilities arising from 
S. Basu and A.N. Shaik  ADMET & DMPK 5(2) (2017) 57-58 
58  
genetic polymorphisms can also affect both drug absorption and disposition which often results in 
inconclusive results. Although the lack of ideal probes and inhibitors has confounded the transporter data 
interpretations for intestinal absorption, the role of efflux in other organs (blood-brain-barrier) is better 
understood.  
With the increasing interest in drug transporters from pharmaceutical companies and regulatory 
authorities alike and following the success of a previous special issue on drug metabolism [1] as well as a 
special issue on drug transporters and permeability (2015, volume 3, issue 1), ADMET & DMPK devoted a 
special issue on “Role of drug transporters in drug development: a qualitative and quantitative approach” 
with the focus to explore the current trend in the uses of these transporters at various stages of drug 
discovery and development. We received a few original articles and two review articles, which covered 
various areas including, uric acid transporters and its inhibitors in gout, perillyl alcohol mediated abrogated 
membrane transport in Candida albicans, use of different fluorescent organic cations for screening against 
OCT2 transporters and expression of drug transporters in human skin and its uses in drug development. 
One particular submission of a great interest was “Consensus rank orderings of molecular fingerprints 
illustrate the ‘most genuine’ similarities between marketed drugs and small endogenous human 
metabolites, but highlight exogenous natural products as the most important ‘natural’ drug transporter 
substrates” where the authors S. O’Hagan and D.B. Kell brought about the similarities between small 
endogenous metabolites and marketed drugs.  
These submissions clearly indicate the utilization of various drug transporters at different stages of drug 
discovery and development. As there has been significant interest in this special issue focussing on drug 
transporters we will follow with a second edition of the special issue to accommodate other submissions. 
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